Rapamune Related Published Studies
Well-designed clinical trials related to Rapamune (Sirolimus)
Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions. [2008.10]
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. [2008.09.27]
Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. [2008.08.27]
A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. [2008.08.26]
In-stent restenosis in bare metal stents versus sirolimus-eluting stents after primary coronary intervention for acute myocardial infarction and subsequent transcoronary transplantation of autologous stem cells. [2008.08]
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. [2008.08]
Intravascular ultrasound assessment of expansion of the sirolimus-eluting (cypher select) and paclitaxel-eluting (Taxus Express-2) stent in patients with diabetes mellitus. [2008.07.01]
Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. [2008.07.01]
Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). [2008.06.15]
Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. [2008.06.01]
Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). [2008.06.01]
Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents. [2008.06]
Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. [2008.06]
The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen. [2008.06]
Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. [2008.05.27]
Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. [2008.05]
Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. [2008.04.27]
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. [2008.04.16]
Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. [2008.04]
Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world' [2008.03]
Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. [2008.03]
Sirolimus reduces polycystic liver volume in ADPKD patients. [2008.03]
Poor Tolerance of Sirolimus in a Steroid Avoidance Regimen for Renal Transplantation. [2008.02.27]
Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. [2008.02.15]
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. [2008.02.12]
Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. [2008.01.30]
Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. [2008.01]
Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. [2008.01]
The effect of sirolimus in the development of chronic allograft nephropathy. [2008.01]
Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina. [2008]
Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. [2007.12.01]
Efficacy of reduced-dose sirolimus-eluting stents in the human coronary artery: serial IVUS analysis of neointimal hyperplasia and luminal dimension. [2007.12.01]
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. [2007.12]
Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. [2007.12]
Gender-specific outcomes after sirolimus-eluting stent implantation. [2007.11.27]
Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. [2007.11]
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). [2007.11]
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. [2007.10.27]
One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. [2007.10.23]
Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. [2007.10.02]
Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine. [2007.10]
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. [2007.09.18]
Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. [2007.09.15]
A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study. [2007.09]
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. [2007.09]
Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. [2007.09]
Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. [2007.08.01]
The effect of sirolimus therapy on vaccine responses in transplant recipients. [2007.08]
Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. [2007.07.17]
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. [2007.07.10]
Intravascular ultrasound comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent] trial). [2007.07.01]
Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. [2007.07]
Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. [2007.07]
The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. [2007.07]
Comparison of stent graft, sirolimus stent, and bare metal stent implanted in patients with acute coronary syndrome: clinical and angiographic follow-up. [2007.06]
Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. [2007.06]
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. [2007.05.31]
Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. [2007.05.27]
Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. [2007.05.20]
Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). [2007.05.15]
Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. [2007.05]
Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years. [2007.05]
Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. [2007.04.15]
Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. [2007.01]
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. [2006.12.19]
Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. [2006.12.19]
Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). [2006.12]
Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. [2006.11.14]
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. [2006.10]
Sirolimus-eluting versus uncoated stents in acute myocardial infarction. [2006.09.14]
Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. [2006.08.29]
Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. [2006.07]
Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. [2006.06.06]
A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. [2006.06.06]
The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial). [2006.06.01]
Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. [2006.06]
"Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study". [2006.06]
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. [2006.03.27]
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. [2006.03.15]
Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. [2006.03]
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. [2006.03]
Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. [2006.02.22]
Comparison between sirolimus- and paclitaxel-eluting stent in T-cell subsets redistribution. [2006.02.15]
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. [2006.02.01]
Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. [2005.12]
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. [2005.11.15]
Impact of asymmetric stent expansion on neointimal hyperplasia following sirolimus-eluting stent implantation. [2005.11.15]
Impact of intravascular ultrasound lesion characteristics on neointimal hyperplasia following sirolimus-eluting stent implantation. [2005.11.01]
Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. [2005.10]
A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. [2005.10]
Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results. [2005.10]
Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. [2005.09]
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. [2005.08.18]
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. [2005.08.18]
A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. [2005.08.15]
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. [2005.08.10]
Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. [2005.07]
Direct stenting with sirolimus-eluting stents. [2005.06]
Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. [2005.05.15]
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. [2005.05.04]
Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. [2005.05]
|
